10x Genomics
219 hedge funds and large institutions have $8.55B invested in 10x Genomics in 2020 Q3 according to their latest regulatory filings, with 89 funds opening new positions, 82 increasing their positions, 37 reducing their positions, and 16 closing their positions.
456% more first-time investments, than exits
New positions opened: 89 | Existing positions closed: 16
327% more call options, than puts
Call options by funds: $32M | Put options by funds: $7.49M
122% more repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 37
57% more capital invested
Capital invested by funds: $5.45B → $8.55B (+$3.1B)
50% more funds holding
Funds holding: 146 → 219 (+73)
38% more funds holding in top 10
Funds holding in top 10: 8 → 11 (+3)
14.58% less ownership
Funds ownership: 105.34% → 90.76% (-15%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity International
Hamilton,
Bermuda
|
+$260M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$210M |
| 3 |
BlackRock
New York
|
+$166M |
| 4 |
Morgan Stanley
New York
|
+$156M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$147M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management II
Larkspur,
California
|
-$210M |
| 2 |
SIAU
SB Investment Advisers (UK)
London,
United Kingdom
|
-$146M |
| 3 |
VMV
Venrock Management VI
Palo Alto,
California
|
-$122M |
| 4 |
FCMI
Foresite Capital Management I
Larkspur,
California
|
-$78.7M |
| 5 |
JCM
JS Capital Management
New York
|
-$47.9M |
TXG Hedge Fund Activity: Q3 2020 in Review
219 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in 10x Genomics (TXG) for Q3 2020, worth a combined $8.55B — up 57% from $5.45B a quarter earlier.
Buyers outnumbered sellers: 89 funds opened new TXG positions and 16 closed out — a net gain of 73 holders — while 82 added to existing stakes and 37 trimmed.
The largest buyer was Fidelity International, opening a new position worth an estimated $260M. The largest seller was Foresite Capital Management II, cutting an estimated $210M.
- 219 institutional investors held 10x Genomics (TXG) as of Q3 2020, up from 146 in Q2 2020.
- Funds reported $8.55B of 10x Genomics stock for Q3 2020, up 57% quarter-over-quarter.
- 89 funds opened new 10x Genomics positions in Q3 2020 and 16 closed out, a net change of +73 holders.
- The largest 10x Genomics buyer in Q3 2020 was Fidelity International, an estimated $260M added.
- The largest 10x Genomics seller in Q3 2020 was Foresite Capital Management II, an estimated $210M sold.
Based on aggregated 13F filings for Q3 2020.